Journal of Clinical Oncology, Vol 24, No 26 (September 10), 2006: pp. 4309-4316
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.2424
Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma
Federico Rojo,
Josep Tabernero,
Joan Albanell,
Eric Van Cutsem,
Atsushi Ohtsu,
Toshihiko Doi,
Wasaburo Koizumi,
Kuniaki Shirao,
Hiroya Takiuchi,
S. Ramon Cajal,
José Baselga
From the Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain; the University Hospital Gasthuisberg, Leuven, Belgium; the National Cancer Center Hospital E, Chiba; the Kitasato University E Hospital, Kanagawa; the National Cancer Centre Hospital, Tokyo; and the Osaka Medical College, Osaka, Japan.
Address reprint requests to José Baselga, MD, Medical Oncology Service, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain; e-mail: jbaselga{at}vhebron.net
Purpose Epidermal growth factor receptor (EGFR) is highly expressed in some gastric cancers and is implicated in cancer cell growth and proliferation. The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
Methods Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d). Tumor biopsies, obtained at screening and on day 28 of treatment, were assessed for biomarker expression using immunohistochemistry and analysis of apoptosis.
Results One hundred sixteen tumor samples from 70 patients were available, 70 were baseline and 46 were on-therapy biopsies. At baseline, levels of EGFR expression significantly correlated with levels of phosphorylated EGFR (pEGFR; P < .001) and Ki67 expression (P = .011), but not with phosphorylated mitogen-activated protein kinase (pMAPK). After gefitinib treatment, levels of pEGFR in tumor cells were significantly reduced (P = .001); this was not the case for pMAPK and phosphorylated Akt (pAkt). However, in some cases gefitinib inhibited pAkt and these tumors had enhanced apoptosis. Likewise, there was a significant correlation between increased exposure to geftinib and enhanced apoptosis.
Conclusion Gefitinib reached the tumors at concentrations sufficient to inhibit EGFR activation in advanced gastric carcinoma patients, although this did not translate into clinical benefit. Overall, intratumoral phosphorylation of MAPK and Akt was not significantly inhibited by gefitinib. However, the finding that decreases in pAkt correlated with enhanced apoptosis deserves further exploration.
Supported by AstraZeneca, Macclesfield, Cheshire, United Kingdom.
Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31, June 3, 2003.
Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher
Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
J. Clin. Oncol.,
June 10, 2009;
27(17):
2863 - 2873.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Herberger, W. Berger, H. Puhalla, K. Schmid, S. Novak, A. Brandstetter, C. Pirker, T. Gruenberger, and M. Filipits
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells
Mol. Cancer Ther.,
June 1, 2009;
8(6):
1547 - 1556.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Rojo, I. Gonzalez-Navarrete, R. Bragado, A. Dalmases, S. Menendez, M. Cortes-Sempere, C. Suarez, C. Oliva, S. Servitja, V. Rodriguez-Fanjul, et al.
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin
Clin. Cancer Res.,
May 15, 2009;
15(10):
3530 - 3539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Chau, A. R. Norman, D. Cunningham, J. Oates, R. Hawkins, T. Iveson, M. Nicolson, P. Harper, M. Seymour, and T. Hickish
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
Ann. Onc.,
May 1, 2009;
20(5):
885 - 891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Burns, Y. Li, C. A. Cheney, Y. Ou, L. L. Franlin-Pfeifer, N. Kuklin, and Z.-Q. Zhang
Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues
J. Histochem. Cytochem.,
March 1, 2009;
57(3):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Clin. Cancer Res.,
October 1, 2008;
14(19):
6277 - 6283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shimura, H. Kataoka, N. Ogasawara, E. Kubota, M. Sasaki, S. Tanida, and T. Joh
Suppression of proHB-EGF Carboxy-Terminal Fragment Nuclear Translocation: A New Molecular Target Therapy for Gastric Cancer
Clin. Cancer Res.,
June 15, 2008;
14(12):
3956 - 3965.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al.
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clin. Cancer Res.,
January 1, 2008;
14(1):
215 - 223.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist,
January 1, 2008;
13(1):
25 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, et al.
Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer
Clin. Cancer Res.,
November 1, 2007;
13(21):
6518 - 6526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Ferry, M. Anderson, K. Beddard, S. Tomlinson, P. Atherfold, J. Obszynska, R. Harrison, and J. Jankowski
A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response
Clin. Cancer Res.,
October 1, 2007;
13(19):
5869 - 5875.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|